Barinthus Biotherapeutics (BRNS) Q3 2025 earnings summary

Executive summary

• Announced a definitive all-stock merger agreement with Clywedog Therapeutics, expected to close in H1 2026, forming a combined company focused on metabolic and autoimmune diseases, including celiac disease, Type 1 and Type 2 diabetes, and to be renamed and listed as Clywedog Therapeutics Holdings, Inc. on NASDAQ.

• Lead candidate VTP-1000 is in Phase 1 for celiac disease, with a strategic shift away from infectious disease and oncology programs.

• Four clinical data milestones are anticipated within 18 months post-merger closing.

• Net loss of $14.6M for Q3 2025 and $55.4M for the nine months ended September 30, 2025; accumulated deficit reached $293.0M.

Financial highlights

• No revenue recognized in Q3 2025, compared to $15.0M in Q3 2024 due to the end of Vaxzevria-related license revenue.

• Cash, cash equivalents, and restricted cash totaled $75.7M as of September 30, 2025, down from $87.8M at June 30, 2025.

• Research and development expenses decreased to $5.4M in Q3 2025 from $11.1M in Q3 2024 and $8.0M in Q2 2025, reflecting pipeline reprioritization and UK lab closure.

• General and administrative expenses fell to $5.2M in Q3 2025 from $13.4M in Q3 2024 and $15.4M in Q2 2025, mainly due to foreign exchange gains and lower personnel costs.

• Impairment charge of $4.7M recorded in Q3 2025 for acquired intangible assets due to the merger agreement.

Outlook and guidance

• Cash resources expected to fund operations into early 2027, supported by new and existing investors.

• Single ascending dose data for VTP-1000 in celiac disease expected by end of 2025; multiple ascending dose data expected in H2 2026.

• No expectation of positive cash flows from operations in the foreseeable future; additional funding may be required if the merger is not completed.